

Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/A6E4C10F97FEN.html>

Date: March 2021

Pages: 48

Price: US\$ 125.00 (Single User License)

ID: A6E4C10F97FEN

Abstracts

Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vaxart Inc (Vaxart), formerly Aviragen Therapeutics Inc, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, which uses state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. Vaxart is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. The company is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer, and dysplasia caused by human papillomavirus (HPV). Vaxart is headquartered in San Francisco, California, the US.

Vaxart Inc Key Recent Developments

Feb 25,2021: Vaxart provides business update and reports fourth quarter and full year 2020 financial results

Jan 28,2021: Vaxart announces resignation of Steven Boyd and Keith Maher

Nov 12,2020: Vaxart reports third quarter 2020 financial results and provides business update

Oct 07,2020: Centaur Biopharmaceutical services announces expansion of manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates

Sep 25,2020: VAXART investigation initiated by Former Louisiana Attorney General: Kahn Swick & Foti investigates the officers and directors of Vaxart - VXRT

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

- Vaxart Inc - Key Facts
- Vaxart Inc - Key Employees
- Vaxart Inc - Key Employee Biographies
- Vaxart Inc - Major Products and Services
- Vaxart Inc - History
- Vaxart Inc - Company Statement
- Vaxart Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

- Company Overview
- Vaxart Inc - Business Description
- Vaxart Inc - Corporate Strategy
- Vaxart Inc - SWOT Analysis
- SWOT Analysis - Overview
- Vaxart Inc - Strengths
- Vaxart Inc - Weaknesses
- Vaxart Inc - Opportunities
- Vaxart Inc - Threats
- Vaxart Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

- Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
- Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Vaxart Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 25, 2021: Vaxart provides business update and reports fourth quarter and full year 2020 financial results

Jan 28, 2021: Vaxart announces resignation of Steven Boyd and Keith Maher

Nov 12, 2020: Vaxart reports third quarter 2020 financial results and provides business update

Oct 07, 2020: Centaur Biopharmaceutical services announces expansion of manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates

Sep 25, 2020: VAXART investigation initiated by Former Louisiana Attorney General: Kahn Swick & Foti investigates the officers and directors of Vaxart - VXRT

Aug 27, 2020: Vaxart appoints Karen J. Wilson to its Board of Directors

Aug 06, 2020: Vaxart announces second quarter 2020 results

Jul 16, 2020: Norovirus gastroenteritis costs an estimated \$10.6 Billion each year in the United States

Jul 13, 2020: Second Virus Wave fears create growing demand for testing, treatments and vaccine candidates

Jun 25, 2020: Vaxart signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Vaxart Inc, Key Facts
Vaxart Inc, Key Employees
Vaxart Inc, Key Employee Biographies
Vaxart Inc, Major Products and Services
Vaxart Inc, History
Vaxart Inc, Subsidiaries
Vaxart Inc, Key Competitors
Vaxart Inc, Annual Ratios
Vaxart Inc, Annual Ratios (Cont...1)
Vaxart Inc, Interim Ratios
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Vaxart Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Vaxart Inc, Performance Chart (2016 - 2020)

Vaxart Inc, Ratio Charts

Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/A6E4C10F97FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A6E4C10F97FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970